60 yo w/ MSS T3N0 tumor: Would you offer Oncotype DX^® assay? If not, what Tx recommend?

Would you offer an Oncotype DX assay for an otherwise healthy 60-year-old patient with a Grade II, microsatellite stable (MSS) T3N0 (0 out of 20 nodes positive) tumor?

If not, what adjuvant systemic therapy would you likely recommend for this patient?

OVERVIEW OF ACTIVITY

Recommended Obinutuzumab and Rituximab Dosing

The recommended dose and schedule of obinutuzumab for the approved regimen with chlorambucil in CLL is:

Cycle 1: 100 mg intravenously on day 1, 900 mg on day 2 and 1,000 mg on days 8 and 15

Cycles 2-6: 1,000 mg administered intravenously every 28 days

The recommended dose and schedule of rituximab for the approved regimen with fludarabine and cyclophosphamide (FC) in CLL is:

375 mg/m² the day prior to the initiation of FC chemotherapy, then 500 mg/m² on day 1 of cycles 2-6 (every 28 days)

OVERVIEW OF ACTIVITY

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

60 yo, 2.1-cm node-neg IDC, ER+/HER2-neg adj TC + AI: Systemic Tx if chest wall recurrence 2 y later and NED?

60 yo woman, s/p mastectomy for a 2.1-cm IDC, negative nodes. Patient receives TC followed by anastrozole, but 2 years after starting anastrozole a small lesion is removed from the chest wall that proves to be a recurrence. No other disease is detected clinically or on imaging. Both the primary tumor and the recurrence are ER-positive/HER2-negative. What systemic treatment would you recommend?

% of pts treated w/ everolimus who require a dose adjustment?

What proportion of your patients receiving everolimus require dose adjustments for toxicity?

Tx PMW ER+/HER2-neg, asymptomatic mets after 3 years adj AI?

What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, higher-volume metastases after receiving adjuvant anastrozole for 3 years?

Tx PMW ER+/HER2-neg, asymptomatic mets after 1 year adj AI?

What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, low-volume metastases after receiving adjuvant anastrozole for 1 year?

60 yo, 2.1-cm node-neg IDC, ER+/HER2-neg adj TC + AI: Systemic Tx if chest wall recurrence 2 y later and NED?

60 yo woman, s/p mastectomy for a 2.1-cm IDC, negative nodes. Patient receives TC followed by anastrozole, but 2 years after starting anastrozole a small lesion is removed from the chest wall that proves to be a recurrence. No other disease is detected clinically or on imaging. Both the primary tumor and the recurrence are ER-positive/HER2-negative. What systemic treatment would you recommend?

% of pts treated w/ everolimus who require a dose adjustment?

What proportion of your patients receiving everolimus require dose adjustments for toxicity?

Tx PMW ER+/HER2-neg, asymptomatic mets after 3 years adj AI?

What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, higher-volume metastases after receiving adjuvant anastrozole for 3 years?

Tx PMW ER+/HER2-neg, asymptomatic mets after 1 year adj AI?

What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, low-volume metastases after receiving adjuvant anastrozole for 1 year?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, breast/general surgeons and other healthcare practitioners involved in the management of breast cancer.

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed type of cancer in women, with an estimated 234,580 new cases and 40,030 deaths in the United States in 2013. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.